BOC Group/Ohmeda suits v. Inhalon employees seek to bar marketing of generic isoflurane, enflurane.
BOC GROUP/OHMEDA SUING INHALON AND EMPLOYEES OVER 39424ISOFLURANE AND ENFLURANE, charging breach of contract by four former Ohmeda employees, conspiracy and misappropriation and misuse of trade secrets to manufacture the inhalation anesthetics. BOC Group, its Ohmeda Pharmaceutical Products Division anesthetics operations (formerly Anaquest) and its Puerto Rico manufacturing arm Ohmeda Caribe announced March 29 that suits have been filed against Bethlehem, Penn.-based Inhalon Pharmaceuticals in the Court of Common Pleas in Northampton County, Penn. that seek monetary damages and an injunction to prevent Inhalon from marketing isoflurane and enflurane.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth